Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
The potential for P450 mediated interactions with other medicinal products involving abacavir is low.
In vitro studies have shown that abacavir has potential to inhibit cytochrome P450 1A1 (CYP1A1).
P450 does not play a major role in the metabolism of abacavir, and abacavir shows limited potential to
inhibit metabolism mediated by CYP 3A4. Abacavir has also been shown in vitro not to inhibit,
CYP2C9 or CYP2D6 enzymes at clinically relevant concentrations. Induction of hepatic metabolism
has not been observed in clinical studies. Therefore, there is little potential for interactions with
antiretroviral PIs and other medicinal products metabolised by major P450 enzymes. Clinical studies
have shown that there are no clinically significant interactions between abacavir, zidovudine, and
lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
6
Riociguat: In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of
riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat AUC(0-∞)
when compared to historical riociguat AUC(0-∞) reported in healthy subjects. Riociguat dose may
need to be reduced. Consult the riociguat prescribing information for dosing recommendations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
24
has not been observed in clinical studies. Therefore, there is little potential for interactions with
antiretroviral PIs and other medicinal products metabolised by major P450 enzymes. Clinical studies
have shown that there are no clinically significant interactions between abacavir, zidovudine, and
lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Riociguat: In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of
riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat AUC(0-∞)
when compared to historical riociguat AUC(0-∞) reported in healthy subjects. Riociguat dose may
need to be reduced. Consult the riociguat prescribing information for dosing recommendations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-01-19T10:13:00Z · SHA-256 5ae0e9d13123c9bc32a3fb0e0e28b30666a7ec0ca822b9a0f255860ec60bcfbd · Passage ea8fcaebe617386f58b28436deabd35b752edd5612b1bc5946d8d2a4157725a9 · Zeichen 2042–2516 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.